Reducing Pain in Experimental Models of Intestinal Inflammation Affects the Immune Response. Issue 5 (6th December 2021)

• Record Type: Journal Article
• Authors: Golusda, Laura; Kühl, Anja A; Siegmund, Britta; Paclik, Daniela
• Is Part Of: Inflammatory bowel diseases. Volume 28:Issue 5(2022)
• Page Start: 801
• Page End: 807
• Publication Date: 2021-12-06
• Subjects: colitis -- inflammation -- inflammatory bowel disease -- opioids -- pain treatment; Inflammatory bowel diseases -- Periodicals; Colitis, Ulcerative -- Periodicals; Crohn Disease -- Periodicals; Inflammatory Bowel Diseases -- Periodicals; 616.344
• DOI: 10.1093/ibd/izab290
• Languages: English
• ISSNs: 1078-0998

Abstract

Abstract: The incidence of inflammatory bowel disease with its two main manifestations, colitis ulcerosa and Crohn's disease, is rising globally year after year. There is still a tremendous need to study the underlying pathomechanisms and a well-established tool in order to better understand the disease are colitis models in rodents. Since the concept of the 3Rs was proposed by Russell and Burch, this would include pain medication in animal models of intestinal inflammation as a reduction of suffering. This review argues against pain medication because the administration of pain medication in its current form has an impact on the inflammatory process and the immune response, thus falsifying the results and the reproducibility and therefore leading to misconceptions. Lay Summary: Colitis models are a good tool to study underlying pathomechanisms of inflammatory bowel disease. Pain medication to fulfill the concept of the 3Rs has to be considered carefully. This review discusses influences of pain medication on the immune system, functional structures, and inflammatory processes.